Boomi Enterprise Platform Delivered 347% ROI and $9.8M NPV, According To New Independent TEI Study
4.9.2025 15:00:00 CEST | Business Wire | Press Release
Boomi™, the leader in AI-driven automation, today announced the results of a new Total Economic Impact™ (TEI) study conducted by Forrester Consulting. The study found that organizations using the Boomi Enterprise Platform achieved a 347% return on investment (ROI) and a net present value (NPV) of $9.8 million over three years, with a payback period of under six months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904005703/en/
Boomi Enterprise Platform Delivered 347% ROI and $9.8M NPV, According To New Independent TEI Study
The study, commissioned by Boomi, evaluates the business benefits, cost savings, and efficiencies realized by enterprises leveraging the Boomi Enterprise Platform for integration, API management, data management, automation, and AI readiness. Based on in-depth interviews with global Boomi customers across the manufacturing, energy, and high-tech sectors, Forrester constructed a composite organization to model the financial impact of deploying Boomi at scale.
Boomi continues to deliver strong value to its customers: the latest Forrester TEI study reports $9.8 million in net present value and a payback period of less than six months — which Boomi believes underscores the rapid time to value and long-term impact of the Boomi Enterprise Platform.
As organizations move beyond traditional digital transformation and into the age of agentic AI — where autonomous systems can plan, act, and adapt — Boomi provides the essential foundation to orchestrate complex workflows with speed, security, and simplicity.
“The stability of the platform and the holistic nature of the automation platform that it gives you is like a single pane of glass. In one application area, you see all your code base, what you’ve deployed, and all the executions on an ongoing basis. We appreciate the ease of use, the reliability, in terms of the executions, and it’s easy to support as well,” an integration architect at a manufacturing company said.
Key quantified benefits over three years include:
- $5.6 million in business and partner productivity gains through workflow automation and real-time data visibility
- $3.0 million in reduced business risk via improved platform reliability, uptime, and compliance
- $1.5 million in technology cost savings from consolidating and retiring legacy platforms
- $1.3 million in IT employee and contractor savings through faster development and reduced maintenance
- $1.2 million in incremental profit from faster delivery of new revenue-generating services
The Boomi Enterprise Platform replaces costly and brittle point-to-point integrations with a unified, low-code solution that simplifies architecture and accelerates time to value. Organizations interviewed by Forrester reported reducing integration timelines by 65%, minimizing errors, and enabling IT and business teams to focus on innovation instead of troubleshooting.
“Boomi is the engine behind some of the world’s most complex, mission-critical automation strategies,” said Steve Lucas, Chairman and CEO of Boomi. “For us, this study validates what our customers already know: when you unify your data, systems, and people with Boomi, you accelerate outcomes and unlock new possibilities — whether you're streamlining operations or preparing for agentic transformation. It's not just integration. It's intelligent automation and orchestration at enterprise scale.”
Boomi eliminates the friction of integration complexity. With pre-built agents and connectors, robust APIs, and drag-and-drop workflows, organizations can dramatically cut integration times from weeks to days and free up IT resources for innovation. The study highlights how the Boomi Enterprise Platform empowers enterprises to modernize legacy systems, improve cross-functional collaboration, and scale efficiently to meet evolving business and technology demands — all while reducing complexity and resource requirements.
Additional unquantified benefits cited by customers include:
- Stronger API security and reduced compliance risk
- Improved employee morale due to fewer after-hours issues
- Increased value from existing infrastructure investments
- Scalable foundation for managing all AI agents via Boomi Agentstudio
Additionally, interviewees noted that Boomi helped eliminate manual overhead and enabled near-real-time data exchange between systems and partners — cutting down on human error and freeing employees to focus on higher-value work.
Additional Resources
- Access the full study: To explore the full Total Economic Impact™ of Boomi, including detailed financial modeling and customer insights, download the report here.
- Follow Boomi on X, LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management, in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250904005703/en/
Contacts
Kristen Walker
Boomi Global Corporate Communications
kristen.walker@boomi.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom